PT - JOURNAL ARTICLE AU - Alyssa Silva-Cayetano AU - William S. Foster AU - Silvia Innocentin AU - Sandra Belij-Rammerstorfer AU - Alexandra J. Spencer AU - Oliver T. Burton AU - Sigrid Fra-Bidó AU - Jia Le Lee AU - Nazia Thakur AU - Carina Conceicao AU - Daniel Wright AU - Jordan Barett AU - Nicola Evans-Bailey AU - Carly Noble AU - Dalan Bailey AU - Adrian Liston AU - Sarah C. Gilbert AU - Teresa Lambe AU - Michelle A. Linterman TI - A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice AID - 10.1101/2020.10.27.357426 DP - 2020 Jan 01 TA - bioRxiv PG - 2020.10.27.357426 4099 - http://biorxiv.org/content/early/2020/10/27/2020.10.27.357426.short 4100 - http://biorxiv.org/content/early/2020/10/27/2020.10.27.357426.full AB - The spread of SARS-CoV-2 has caused a global pandemic that has affected almost every aspect of human life. The development of an effective COVID-19 vaccine could limit the morbidity and mortality caused by infection, and may enable the relaxation of social distancing measures. Age is one of the most significant risk factors for poor health outcomes after SARS-CoV-2 infection, therefore it is desirable that any new vaccine candidates should elicit a robust immune response in older adults. Here, we test the immunogenicity of the adenoviral vectored vaccine ChAdOx1 nCoV-19 (AZD-1222) in aged mice. We find that a single dose of this vaccine induces cellular and humoral immunity in aged mice, but at a reduced magnitude than in younger adult mice. Furthermore, we report that a second dose enhances the immune response to this vaccine in aged mice, indicating that a primeboost strategy may be a rational approach to enhance immunogenicity in older persons.Competing Interest StatementSarah Gilbert and Teresa Lambe are named on a patent application covering ChAdOx1 nCoV-19. The remaining authors declare no competing interests. The funders played no role in the conceptualisation, design, data collection, analysis, decision to publish, or preparation of the manuscript.